Alkermes (NASDAQ:ALKS – Get Free Report) and Immuneering (NASDAQ:IMRX – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.
Institutional and Insider Ownership
95.2% of Alkermes shares are owned by institutional investors. Comparatively, 67.7% of Immuneering shares are owned by institutional investors. 4.9% of Alkermes shares are owned by company insiders. Comparatively, 25.0% of Immuneering shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Alkermes and Immuneering, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Alkermes | 1 | 2 | 9 | 0 | 2.67 |
| Immuneering | 1 | 3 | 4 | 0 | 2.38 |
Valuation and Earnings
This table compares Alkermes and Immuneering”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Alkermes | $1.66 billion | 3.49 | $355.76 million | $1.95 | 18.41 |
| Immuneering | $320,000.00 | 180.48 | -$53.47 million | ($1.97) | -0.94 |
Alkermes has higher revenue and earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Alkermes has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Comparatively, Immuneering has a beta of -0.36, meaning that its share price is 136% less volatile than the S&P 500.
Profitability
This table compares Alkermes and Immuneering’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Alkermes | 22.15% | 24.92% | 14.55% |
| Immuneering | N/A | -79.19% | -69.08% |
Summary
Alkermes beats Immuneering on 11 of the 14 factors compared between the two stocks.
About Alkermes
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
About Immuneering
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.
